Welcome to our dedicated page for Precision Optics news (Ticker: POCI), a resource for investors and traders seeking the latest updates and insights on Precision Optics stock.
Precision Optics Corporation, Inc. reports recurring business developments in advanced optical instruments for the medical and defense/aerospace industries. The company designs, develops and manufactures custom optical medical devices, endoscopes, endocouplers and related optical assemblies, with news frequently covering single-use endoscopy programs and customer production orders.
Updates for POCI also include product-development work for aerospace and defense applications, including small-diameter borescope systems used in jet-engine inspection. Company announcements commonly address fiscal-period operating results, conference calls, customer program activity, backlog and pipeline commentary, and capital-structure actions involving its Nasdaq-listed common stock.
Precision Optics Corporation (Nasdaq: POCI) announced a conference call scheduled for February 14, 2023, at 5:00 PM ET to discuss its financial results for the first quarter of fiscal year 2023. The company will release its financial results and file its 10-Q after the market closes on the same day. Interested parties can access the call by dialing (844) 735-3662 or through a live webcast at here. A replay of the call will be available until February 21, 2023. Founded in 1982, Precision Optics specializes in advanced optical instruments for medical and defense sectors, leveraging proprietary technologies.
Precision Optics Corporation (NASDAQ: POCI) announced that CEO Dr. Joe Forkey will present at the Lytham Partners Investor Select Conference on January 31, 2023. The event will take place virtually, allowing for one-on-one meetings with investors. Attendees can view the company's webcast presentation at 9:00 AM ET on the same day via the company's website or through the provided webcast link. Precision Optics specializes in designing and manufacturing advanced optical instruments for the medical and defense industries and has significant expertise in micro-optics and 3D imaging technologies.
Precision Optics Corporation (NASDAQ: POCI) announced a follow-on production order worth approximately $2.3 million from a major medical device company for an otoscopy application, expected to be delivered within 12 to 24 months, starting early 2023. This order comes after production was halted for over 24 months due to the pandemic. The company's CEO, Dr. Joe Forkey, expressed optimism about the ongoing production orders and growth anticipated for this fiscal year. Precision Optics specializes in advanced optical instruments for healthcare and defense sectors, utilizing proprietary technologies in their offerings.
Precision Optics Corporation (NASDAQ:POCI) announced a follow-on production order worth $2.6 million from a major US defense contractor. This new order reflects a three-fold increase from previous orders and is expected to be fulfilled over the next 12 to 18 months. The demand for this complex optical assembly has been strong since 2018, encouraging future renewals of production orders. CEO Dr. Joe Forkey emphasized that this growth supports anticipated revenue increases for the fiscal year and beyond, underlining the company's solid relationship with its defense contractor client.
Precision Optics Corporation (Nasdaq: POCI) announced that CEO Joe Forkey and team will ring the Nasdaq opening bell on December 14, 2022. This event celebrates the company’s recent uplisting and a year marked by record revenues driven by a growing production portfolio and a robust product development pipeline. Forkey emphasized that the event is a tribute to the hard work of employees who contribute to advancing optical innovation in medical and defense sectors.
Precision Optics Corporation (NASDAQ: POCI) has announced a $750,000 product development order for a next-generation single-use urology program from an established medical device company. This program is the second single-use project moving past the proof-of-concept phase and leverages the combined expertise of Precision Optics and Lighthouse Imaging. The development effort will span one to two years, with anticipated production orders following successful validation. The CEO emphasized the industry’s recognition of their capabilities in micro-optics and the importance of single-use products for future growth.